Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Indivior Solutions ordered to pay $289 million in Suboxone case

By Brian Buntz | November 14, 2020

IndiviorA federal judge in Virginia has sentenced opioid-addiction drug maker Indivior Solutions (LON:INDV) to pay $289 million in criminal penalties linked to the marketing of the drug Suboxone, the U.S. Department of Justice announced. 

In all, Indivior will pay a total of $600 million to resolve civil and criminal liabilities for downplaying safety risks tied to Suboxone. 

Randy Ramseyer of the U.S. Attorney’s Office for the Western District of Virginia prosecuted the case against Indivior. 

The company’s former parent, Reckitt Benckiser Group, agreed last year to pay $1.4 billion to the Department of Justice to settle Suboxone-related complaints. The amount was the largest sum the U.S. has recovered in an opioid drug case. 

The opioid-addiction treatment combines the opioid buprenorphine and naloxone, a drug that blocks the effects of opioids. The drug is intended to reduce withdrawal symptoms in opioid addicts. 

Indivior Solutions pleaded guilty thus summer to a single felony related to making false healthcare statements. 

The company also admitted to making false claims regarding the risk of Suboxone sublingual film use in children. 

The company also will disband its Suboxone sales force and avoid promoting the drug to healthcare providers likely to prescribe the medication inappropriately. 

“Combating the opioid epidemic is a top priority for the Department of Justice,” said Acting Assistant Attorney General Jeffrey Bossert Clark of the Justice Department’s Civil Division in prepared remarks. “We will hold drug manufacturers accountable when they make misrepresentations that could affect consumers’ access to opioid addiction treatments.”

Indivior’s former CEO, Shaun Thaxter, pleaded guilty on June 30, 2020, to a misdemeanor related to making false and misleading statements to MassHealth. The court sentenced Thaxter to a six-month prison term and $600,000 in criminal fines and forfeiture. 

Thaxter had been CEO since 2009. 

The company’s former medical director, Tim Baxter, pleaded guilty to a similar charge and is scheduled for sentencing in December. 

 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Comments

  1. Robin Hartman says

    May 30, 2021 at 2:03 pm

    I was put on Suboxone ten years ago in a hospital in Kingston, New York. I am not a heroin addict. I was given this drug so I could stop pain medication. I have not needed this drug for almost that long, but I am unable to stop using it because of excruciating withdrawal symptoms. Suboxone has cause me $9,000 worth of dental problems. It has caused me to lose 2 jobs. (It makes you appear high). It has caused relationship problems, loss of motivation. Suboxone is being prescribed to millions of unsuspecting people who are doomed to the same fate. A dozen lawyers have refused my case. I am not giving up. I deserve financial compensation. Indivior needs to take care of cumtomers who have been harmed. I am hoping you can help.

    Reply

Tell Us What You Think! Cancel reply

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE